Indications
In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2).
Composition
- Active substance
- spironolactone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Qaialdo
- Active substance
- spironolactone
- ATC code
- C03DA01
- Therapeutic area
- Edema, Heart Failure, Liver Cirrhosis, Ascites, Nephrotic Syndrome, Hyperaldosteronism, Essential Hypertension